Self-Amplifying Pestivirus Replicon RNA Encoding Influenza Virus Nucleoprotein and Hemagglutinin Promote Humoral and Cellular Immune Responses in Pigs

• Published in: Frontiers in immunology 2021-01, Vol.11, p.622385-622385
• Main Authors: Démoulins, Thomas, Ruggli, Nicolas, Gerber, Markus, Thomann-Harwood, Lisa J, Ebensen, Thomas, Schulze, Kai, Guzmán, Carlos A, McCullough, Kenneth C
• Format: Article
• Language: English
• Subjects: Animals; c-di-AMP adjuvant; COVID-19; Hemagglutinin Glycoproteins, Influenza Virus - immunology; humoral and cellular immune response; Immunity, Cellular; Immunity, Humoral; Immunology; Influenza A Virus, H5N1 Subtype - immunology; influenza vaccines; Influenza Vaccines - administration & dosage; Influenza Vaccines - immunology; Pestivirus; polyplexes; Replicon - immunology; RNA, Viral - administration & dosage; RNA, Viral - immunology; SARS-CoV-2; self-amplifying replicon RNA; Swine; Viral Core Proteins - immunology; virus replicon particle
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2020.622385

Self-amplifying replicon RNA (RepRNA) promotes expansion of mRNA templates encoding genes of interest through their replicative nature, thus providing increased antigen payloads. RepRNA derived from the non-cytopathogenic classical swine fever virus (CSFV) targets monocytes and dendritic cells (DCs), potentially promoting prolonged antigen expression in the DCs, contrasting with cytopathogenic RepRNA. We engineered pestivirus RepRNA constructs encoding influenza virus H5N1 (A/chicken/Yamaguchi/7/2004) nucleoprotein (Rep-NP) or hemagglutinin (Rep-HA). The inherent RNase-sensitivity of RepRNA had to be circumvented to ensure efficient delivery to DCs for intracellular release and RepRNA translation; we have reported how only particular synthetic delivery vehicle formulations are appropriate. The question remained concerning RepRNA packaged in virus replicon particles (VRPs); we have now compared an efficient polyethylenimine (PEI)-based formulation (polyplex) with VRP-delivery as well as naked RepRNA co-administered with the potent bis-(3',5')-cyclic dimeric adenosine monophosphate (c-di-AMP) adjuvant. All formulations contained a Rep-HA/Rep-NP mix, to assess the breadth of both humoral and cell-mediated defences against the influenza virus antigens. Assessment employed pigs for their close immunological relationship to humans, and as natural hosts for influenza virus. Animals receiving the VRPs, as well as PEI-delivered RepRNA, displayed strong humoral and cellular responses against both HA and NP, but with VRPs proving to be more efficacious. In contrast, naked RepRNA plus c-di-AMP could induce only low-level immune responses, in one out of five pigs. In conclusion, RepRNA encoding different influenza virus antigens are efficacious for inducing both humoral and cellular immune defences in pigs. Comparisons showed that packaging within VRP remains the most efficacious for delivery leading to induction of immune defences; however, this technology necessitates employment of expensive complementing cell cultures, and VRPs do not target human cells. Therefore, choosing the appropriate synthetic delivery vehicle still offers potential for rapid vaccine design, particularly in the context of the current coronavirus pandemic.